Judges Scientific plc JDG
London Stock Exchange - AIMElectronic components and instrumentsFinancials to Jun 30, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| £M | Dec 31 | Jun 30 |
|---|---|---|
| Cash | 19.4 | 15.6 |
| Securities | 0.0 | 0.0 |
| Debt | 59.6 | 58.6 |
| Net cash | -40.2 | -43.0 |
| Equity | 83.7 | 83.2 |
- Debt / EBITDA
- 2.92×
- Debt / equity
- 0.70×
- Leases (6/30/26)
- £5M
- Diluted shares
- 7M
- Book value / share
- £12.49
- Price / book
- 2.7×
- Net cash / share
- −£6.46
- Market cap
- £228M
- Enterprise value
- £271M
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 halves |
|---|---|---|---|
| Revenue growth | -20.7% | -36.1 pts | |
| Operating margin | -0.7% | -12.7 pts | |
| FCF margin | -0.5% | -11.8 pts | |
| Capex / revenue | 4.8% | +0.7 pts | |
| Order book | 17 | – | |
| Group order intake growth | -12% | – | – |
| Materials Sciences revenue (H1) | £25M | -30% | |
| Vacuum revenue (H1) | £31M | -11% | |
| Materials Sciences revenue · 12/31/25 | £72M | +11% |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About JDG
Judges Scientific owns 25 small scientific-instrument businesses serving research laboratories and industrial customers. FY2025 sales were 49.3% Materials Sciences and 50.7% Vacuum.
- Brand Trust
Judges says quality and service reputation matter in its subsidiaries' small scientific-instrument niches, where performance can be difficult to assess before use.
- Brand Trust
Judges says quality and service reputation matter in its subsidiaries' vacuum and surface-science niches.
- Sep 23, 2026
Judges extended its bank facilities to July 2030 on unchanged covenants, reducing near-term refinancing pressure while acquisition funding remains subject to cash generation and leverage.
- Sep 23, 2026
CFO Brad Ormsby announced he will step down by 23 September 2027; the twelve-month handover gives the new CEO time to appoint a successor.
- Sep 23, 2026
Judges reported a GBP1.7m first-half pretax loss and retained full-year earnings guidance after summer order recovery, leaving a larger share of revenue dependent on Q4 delivery.
- Aug 2026
Armfield completed its defined-benefit pension buyout in August 2026, transferring the scheme to an insurer and reducing future pension funding risk; Judges disclosed completion in its September investor presentation.
- Feb 9, 2026
Tim Prestidge became CEO and founder David Cicurel became non-executive Chair, putting operating execution under new leadership while retaining founder guidance.
Ownership
Go deeper on JDG
- Compare stock research toolsFundamentals, valuation and screening platforms for JDG.19 tools
- See JDG's price chartNo price chart here yet. See price history and indicators.17 tools
- Read JDG's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.91 deals
On this page
Financial record
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | Trend | Change 2016–25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share (£) | |||||||||||||
| Revenue | 9.26 | 11.52 | 12.41 | 13.03 | 12.50 | 14.27 | 17.61 | 20.56 | 19.80 | 21.59 | 19.72 | +9.9%/yr | |
| Cash flow | 0.75 | 1.70 | 2.12 | 2.67 | 1.92 | 2.72 | 3.41 | 4.00 | 4.22 | 4.38 | 3.18 | +21.8%/yr | |
| Earnings | 0.01 | 0.65 | 1.35 | 1.80 | 1.29 | 1.98 | 1.94 | 1.43 | 1.54 | 0.81 | -0.09 | +58.2%/yr | |
| Free cash flow | 0.61 | 1.58 | 1.97 | 2.46 | 1.72 | 2.18 | 2.18 | 3.11 | 3.28 | 3.32 | 2.13 | +20.7%/yr | |
| Capex | 0.14 | 0.12 | 0.15 | 0.21 | 0.20 | 0.54 | 1.23 | 0.89 | 0.95 | 1.07 | 1.05 | +25.8%/yr | |
| Dividends | 0.26 | 0.28 | 0.34 | 2.39 | 0.51 | 0.57 | 0.68 | 0.86 | 0.96 | 1.05 | 1.07 | +17.0%/yr | |
| Book value | 3.45 | 3.81 | 4.88 | 4.40 | 5.04 | 6.69 | 8.45 | 12.45 | 12.88 | 12.39 | 12.49 | +15.3%/yr | |
| Diluted shares (M) | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 7 | +1.0%/yr | |
| Totals (£M) | |||||||||||||
| Revenue | 57.3 | 71.4 | 77.9 | 82.5 | 79.9 | 91.3 | 113.2 | 136.1 | 133.6 | 145.8 | 131.3 | +10.9%/yr | |
| Operating income | 1.0 | 5.7 | 10.7 | 14.1 | 10.2 | 15.6 | 18.2 | 21.6 | 16.7 | 13.9 | 5.1 | +34.1%/yr | |
| Net income | 0.1 | 4.0 | 8.5 | 11.4 | 8.2 | 12.7 | 12.5 | 9.5 | 10.4 | 5.5 | -0.6 | +59.8%/yr | |
| Free cash flow | 3.8 | 9.8 | 12.4 | 15.6 | 11.0 | 14.0 | 14.0 | 20.6 | 22.1 | 22.4 | 14.2 | +21.9%/yr | |
| Buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | – | |
| Dividends | 1.6 | 1.7 | 2.1 | 15.1 | 3.2 | 3.6 | 4.4 | 5.7 | 6.5 | 7.1 | 7.1 | +18.2%/yr | |
| Net cash | -8.6 | -7.6 | 0.7 | -0.3 | -5.7 | 1.4 | -34.8 | -44.7 | -49.7 | -40.2 | -43.0 | −£31.6M | |
| Margins & returns (%) | |||||||||||||
| Operating margin | 1.7 | 7.9 | 13.7 | 17.1 | 12.7 | 17.1 | 16.1 | 15.9 | 12.5 | 9.5 | 3.9 | +7.8 pts | |
| Net margin | 0.1 | 5.6 | 10.9 | 13.8 | 10.3 | 13.9 | 11.0 | 7.0 | 7.8 | 3.8 | -0.5 | +3.6 pts | |
| FCF margin | 6.6 | 13.7 | 15.9 | 18.9 | 13.7 | 15.3 | 12.4 | 15.1 | 16.5 | 15.4 | 10.8 | +8.8 pts | |
| ROIC | 2.6 | 14.0 | 27.5 | 38.6 | 20.7 | 29.1 | 15.8 | 13.1 | 9.4 | 8.7 | 3.1 | +6.1 pts | |
| Return on equity | 0.4 | 17.0 | 27.7 | 40.8 | 25.5 | 29.6 | 23.0 | 11.5 | 12.0 | 6.6 | -0.7 | +6.2 pts | |
| R&D % of revenue | 6.6 | 5.0 | 5.9 | 6.4 | 7.7 | 5.9 | 4.7 | 4.1 | 5.2 | 5.8 | – | -0.8 pts | |
| Stock pay % of revenue | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.7 | 0.6 | 0.9 | 1.0 | 1.0 | 0.9 | +0.5 pts | |
| Capex % of revenue | 1.5 | 1.0 | 1.2 | 1.6 | 1.6 | 3.8 | 7.0 | 4.3 | 4.8 | 4.9 | 5.3 | +3.5 pts | |
Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Competitive
- Durability
- medium
- Trajectory
- stable
- Pricing power
- weak
- Materials Sciences49.3%1 claim
- Vacuum50.7%1 claim
Moat claims
- Applies to
- Materials Sciences
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 8, 2026
Judges says quality and service reputation matter in its subsidiaries' small scientific-instrument niches, where performance can be difficult to assess before use. The mechanism may support trust at individual brands, but no independent retention, win-rate, or price evidence demonstrates a group-wide barrier.
H1 2026 group orders fell 12% and sales fell 21%, while eight businesses grew. Weak funding and project demand have not established a loss of customer preference; subsidiary brand trust remains modest and unproven across the portfolio.
- Materials Sciences revenue£72M+11%
- Order book17
- Organic order intake growth-6%
- Group order intake growth-12%
- Research and development spending£10M+21%
- Materials Sciences revenue (H1)£25M-30%
- Reputation damage from quality failures
- Competitors matching specifications or service quality
- Research-funding and project cycles overwhelming brand preference
- SourceJudges Scientific plc Annual report and accounts 2025Apr 21, 2026
- NewsJudges Scientific plc Half Year Trading Update and Notice of Interim ResultsJul 23, 2026
- SourceJudges Scientific interim results, 30 June 2026Sep 23, 2026
- Applies to
- Vacuum
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 8, 2026
Judges says quality and service reputation matter in its subsidiaries' vacuum and surface-science niches. Reliability can affect customer trust, but no independent retention, win-rate, installed-base, or price evidence demonstrates a durable barrier across this diverse segment.
H1 2026 group orders fell 12% and sales fell 21%, while eight businesses grew. Weak funding and project demand have not established a loss of customer preference; subsidiary brand trust remains modest and unproven across the portfolio.
- Vacuum revenue£74M+7%
- Order book17
- Organic order intake growth-6%
- Group order intake growth-12%
- Research and development spending£10M+21%
- Vacuum revenue (H1)£31M-11%
- Competitors matching reliability, specifications, or service quality
- Field failures or delivery delays damaging subsidiary brands
- Project and research-funding cycles overwhelming brand preference
- SourceJudges Scientific plc Annual report and accounts 2025Apr 21, 2026
- NewsJudges Scientific plc Half Year Trading Update and Notice of Interim ResultsJul 23, 2026
- SourceJudges Scientific interim results, 30 June 2026Sep 23, 2026
Profile change log
- Oct 9, 2026 · analyst revision
Verified the statutory history and current demand debate against company reports. Corrected the CEO transition date to 9 February 2026, separated annual and first-half segment sales for comparable growth, and added the different effects of interest hedges and sterling on the business. Moat strength, confidence and direction are unchanged.
- Oct 9, 2026 · business change
Armfield completed its defined-benefit pension buyout in August 2026, transferring the scheme to an insurer and reducing future pension funding risk; Judges disclosed completion in its September investor presentation.
- Oct 8, 2026 · business change
Judges reported a GBP1.7m first-half pretax loss and retained full-year earnings guidance after summer order recovery, leaving a larger share of revenue dependent on Q4 delivery.
- Oct 8, 2026 · business change
CFO Brad Ormsby announced he will step down by 23 September 2027; the twelve-month handover gives the new CEO time to appoint a successor.
- Oct 8, 2026 · business change
Judges extended its bank facilities to July 2030 on unchanged covenants, reducing near-term refinancing pressure while acquisition funding remains subject to cash generation and leverage.
- Oct 8, 2026 · business change
Tim Prestidge became CEO and founder David Cicurel became non-executive Chair, putting operating execution under new leadership while retaining founder guidance.
- Oct 8, 2026 · business change
Geotek bought the remaining 18% of Geotek do Brasil for BRL13m initially plus excess cash and earn-out, giving Judges full ownership of its Brazilian core-digitisation business; instalments create a future cash obligation.
- Oct 8, 2026 · business change
Judges bought Rockwash for GBP2.25m initially with an earn-out of up to GBP3.75m, extending Geotek into digital drill-cuttings analysis; weak performance later eliminated the earn-out.
- Oct 8, 2026 · analyst revision
Removed segment operating-profit shares because GBP6.3m of FY2025 central costs are unallocated. Added demand-sensitive moat trajectories, current management, the investment debate and linked market conditions; moat strength and confidence are unchanged.
Industry & peers
Peer map
Hover a point for its values; click a peer to compare. Dashed lines: industry medians.
Process, analytical and precision measurement instruments
Industrial process analyzers, laboratory and radiation instruments, metrology and precision measurement systems, vacuum and surface-science equipment, geological sample-analysis systems and related technical services, and specialist medical diagnostic instruments. This is a portfolio of separate product niches, excluding general-purpose factory automation, drug development services and semiconductor production equipment.
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| JDG | 29 | – | 3.9% | |
| Industry median | 10 | 62 | 48.2% | 18.0% |
| Sector median | 88 | 76 | 37.3% | 18.0% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Industrial, laboratory and semiconductor capital spending strongly affects new instrument orders. Precision requirements and advanced manufacturing support long-run demand but do not remove investment cycles. Academic grants, pharmaceutical research and industrial capital budgets drive chromatography, mass spectrometry and microscopy orders. Q2 FY2026 Thermo Fisher Analytical Instruments organic revenue rose 7% after a 2% Q1 decline, showing that demand can change quickly. Battery development, semiconductor production and industrial research diversify demand away from academic grants. Eight Judges subsidiaries grew in H1 2026, partly supported by these applications.
- Environmental, nuclear-safety and medical requirements have a moderate to strong effect on measurement and validation spending. Regulatory compliance can create repeat service demand. Food, water and environmental method requirements support applied laboratory measurements. EPA-approved GC-MS/MS methods include several manufacturers, so validated workflows favor qualified platforms without excluding all competitors.
- Interest rates have a moderate indirect effect by changing customer investment budgets. Specialized instruments are a small part of total project spending, which can soften the effect for critical applications. Currency has a material translation and sourcing effect for global vendors. AMETEK reported 52% of EIG sales outside the United States in 2025.
- Better sensors, software and measurement performance drive replacement cycles. Incumbents must keep investing because technically superior competing products can win new projects.
- Public research funding has a strong direct effect on academic instrument orders. Judges reported H1 2026 group order intake down 12%, with US orders down 7%, and expects funding uncertainty to continue into 2027. Government procurement rules can strongly affect order timing without changing the underlying research need. Judges reported China and Hong Kong orders down 47% in H1 2026 as new R&D tax-exemption processes delayed purchases; early resolution appeared by September.
- Project delays and customer inventory corrections can reduce orders even when suppliers retain installed positions. Offshore-wind investment and funded geological expeditions create large, irregular equipment and service orders. Judges expects no Geotek coring expedition in 2027, with a previously discussed customer project delayed until at least 2028. Year-end shipment concentration raises execution risk when orders recover late. Judges expects an unusually large share of 2026 sales in Q4 after summer order improvement; instrument completion, acceptance and customer readiness can delay revenue.
- Numerous vendors compete on product performance, service and price. A strong position in radiation detection does not establish leadership in every analytical or metrology niche. Third-party consumables and service providers can compete with instrument vendors. Companywide recurring-revenue mix does not establish proprietary consumable attachment for every instrument.
- Electronic components, specialized materials, tariffs and export controls can raise costs or delay customer projects. Currency moves affect export competitiveness and translated results; interest rates affect customer projects and debt-funded acquisitions. The effect varies by product and financing structure and does not establish uniform pricing power. Exporters can hedge booked orders while remaining exposed to currency moves in future tenders; interest swaps can soften immediate rate changes without protecting customer investment budgets.
- Acquisitions expand product scope and can dilute margins. Acquired revenue must be separated from organic demand when comparing suppliers.
- Healthcare, nuclear and environmental approvals can delay launches and create recall or liability costs. Approved alternative analytical methods, instrument tenders and compatible software can limit lock-in in chromatography and spectroscopy. These laboratory economics do not establish the same protection in every process, radiation or metrology niche.
Bulls & bears
Can trusted niche instrument businesses rebuild organic orders and cash earnings while public research budgets remain weak, without relying on acquisitions or rare coring expeditions?
Arguments
What to watch
- 1Organic order intake and order-book weeks, with Geotek expeditions separated
- 2Materials Sciences and Vacuum sales and operating profit
- 3Operating cash flow, adjusted gearing and acquisition returns
Next check: The FY2026 trading update and annual results in early 2027 should show whether Q4 shipments converted the order recovery into cash; the dates are not confirmed. Monitor the CFO appointment and US funding decisions meanwhile.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 29/100 by <a href="https://www.findmymoat.com/stocks/AIMX:JDG">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.